Results 241 to 250 of about 61,606 (299)

Continuum of care after newborn screening for sickle cell disease: Multinational evidence from a systematic review and meta-analysis. [PDF]

open access: yesBr J Haematol
Rehman T   +9 more
europepmc   +1 more source

Hydroxyurea

Archives of Dermatology, 1970
In a double-blind study, nine of ten cases of severe psoriasis demonstrated clinical and histopathologic response to hydroxyurea. No toxic reactions were noted. The drug may be less toxic than methotrexate and is efficacious in the management of psoriasis.
Robert B. Livingston, Stephen K. Carter
openaire   +2 more sources

Hydroxyurea therapy

Journal of the American Academy of Dermatology, 1991
Hydroxyurea's place in the scheme of psoriasis therapy has diminished in recent years. Some practitioners mistakenly believe that it is used only in desperate situations, is of little or no benefit in patients unresponsive to more conventional systemic therapies, and may predispose patients to the development of secondary malignancies.
A S, Boyd, K H, Neldner
openaire   +2 more sources

Hydroxyurea

Mutation Research/Reviews in Genetic Toxicology, 1975
Hydroxyurea (HU) is an anti-leukaemia and anti-tumour drug which has also found limited application in the treatment of dermatological disorders. It is a potent inhibitor of DNA synthesis in many organisms from viruses to man and in cell culture systems. To a lesser degree it can also inhibit RNA and protein synthesis.
openaire   +2 more sources

Hydroxyurea derivatives—1-methyl-1-hydroxyurea and 1-ethyl-1-hydroxyurea

Biochemical Pharmacology, 1968
Abstract Certain aspects of the biochemical pharmacology of 1-methyl-1-hydroxyurea (MHU) and 1-ethyl-1-hydroxyurea (EHU) were investigated and were contrasted with the actions of hydroxyurea (HU). Assay of inhibitory action against DNA synthesis in an ascites tumor cell system in vitro revealed an order of relative potentcy of MHU > HU > EHU ...
openaire   +2 more sources

Hydroxyurea and macrocytosis

British Journal of Dermatology, 2006
SUMMARY Nine patients who were treated for psoriasis with hydroxyurea displayed peripheral macrocytosis. Mild megaloblastic changes were also seen in the bone marrow of three patients. One patient receiving hydroxyurea developed mild anaemia, another leukopenia. Macrocytosis did not appear to be secondary to an alteration in serum B12 or folate levels.
S, Spier   +3 more
openaire   +3 more sources

HYDROXYUREA INDUCED HEPATITIS

Medical Journal of Australia, 1980
A case of hydroxyurea-induced self-limited hepatitis with an influenza-like reaction to hydroxyurea therapy is presented. The association was supported by recurrence of the symptoms on rechallenge with the drug.
R, Heddle, A F, Calvert
openaire   +2 more sources

Hydroxyurea Administered Intermittently

JAMA: The Journal of the American Medical Association, 1965
THE SYNTHESIS of hydroxyurea (Hydrea) was reported in 1869 by Dresler and Stein. 1 In animal studies, Rosenthal et al 2 found that the compound produced anemia, severe leukopenia, and megaloblastic changes in the peripheral blood and bone marrow. Recently, this compound has been introduced into cancer chemotherapy. Tumor responses have been observed in
H J, LERNER, G L, BECKLOFF
openaire   +2 more sources

Home - About - Disclaimer - Privacy